Related Experiment Videos
Pathology induced by leukemia inhibitory factor
1Institut für Toxikologie, Eidgenössischen Technischen Hochschule Universität Zürich, Switzerland.
International Review of Experimental Pathology
|January 1, 1993
Summary
Leukemia inhibitory factor (LIF) shows broad biological effects, including hematopoiesis stimulation. However, in vivo studies reveal significant toxicity, indicating a narrow safety margin for therapeutic use.
Area of Science:
- Biochemistry and Molecular Biology
- Hematology
- Regenerative Medicine
Background:
- Leukemia inhibitory factor (LIF) is a pleiotropic glycoprotein with diverse biological functions.
- LIF influences key cellular processes including growth, differentiation, and hematopoiesis.
Purpose of the Study:
- To investigate the multifaceted activities of Leukemia inhibitory factor (LIF).
- To evaluate the in vivo effects and safety profile of LIF, particularly concerning hematopoiesis.
Main Methods:
- Review of existing literature on Leukemia inhibitory factor (LIF) activities.
- Analysis of in vivo study outcomes in animal models (rodents and monkeys) following LIF administration.
Main Results:
- Leukemia inhibitory factor (LIF) demonstrates potent effects on hematopoietic progenitor cells.
- LIF exhibits bone regeneration, cachexia induction, acute-phase response in hepatocytes, and adipogenesis inhibition.
- In vivo LIF treatment in animal models induced general toxicity, cachexia, acute-phase reactions, and hematopoiesis stimulation.
Conclusions:
- Leukemia inhibitory factor (LIF) possesses significant therapeutic potential, especially for hematopoietic disorders.
- The therapeutic application of LIF is constrained by a narrow safety margin due to observed systemic toxicity.